Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

EST Globus Medical (GMED) to acquire Nevro (NVRO) for $5.85 per share Published first on TheFly – the ultimate source for real-time, ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Audubon, PA-based Globus Medical, Inc. is a medical device company ... Zacks Investment Research has been committed to providing investors with tools and independent research since 1978.

Globus Medical GMED has seen impressive momentum in the past year, with its shares soaring 62.1%. It has significantly outperformed the industry’s 7.3% rise and the S&P 500 composite’s 24.8% gain.

09:31 EST Globus Medical (GMED) to acquire Nevro (NVRO) for $5.85 per share Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make ...